Future for VHL kidney cancer is bright
Von Hippel-Lindau (VHL) disease–associated renal cell carcinoma (RCC) has always [...]
ESMO Virtual 2020: HIF-2a MK-6482 in Von Hippel-Lindau Disease and kidney cancer
At the European Society of Medical Oncology (ESMO) Virtual Congress [...]
ASCO 2020: HIF-2 alpha inhibitor induced positive response for VHL-associated kidney cancer
Results from a phase II international trial led by researchers [...]
Novel HIF-2a inhibitor for patients with advanced kidney cancer
In this interview with Practice Update, Dr Eric Jonasch from [...]
ASCO GU 2020: Randomised clinical trial of HIF-2α inhibitor in patients with advanced kidney cancer
A randomised clinical trial of hypoxia inducible factor 2α (HIF-2α) [...]
VHL disease and HIF-2alpha inhibitor
In this video interview, Dr Eric Jonasch from MD Anderson [...]
ESMO 2019: First in human study of HIF-2α inhibitor in patients with advanced kidney cancer
Results from the first in human study of the HIF-2α [...]
HIF-2α inhibitor shows promise in patients with advanced kidney cancer
A recent phase I/II clinical trial with PT2977, a hypoxia-inducible [...]
A new class of anti-cancer drug for kidney cancer shows promise
Researchers in America are looking at a new class of [...]
HIF-2α inhibitor shows promise in renal cell carcinoma
The results of a first-in-human phase I clinical trial with [...]
